Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi To Use Ranbaxy Buy To Enter Africa, East Europe

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo plans to expand into Eastern European and African markets by taking advantage of the network of Ranbaxy Laboratories, which Daiichi is acquiring. The Japanese company plans to own more than 50.1 percent of Ranbaxy by December, enabling it to apply for foreign drug-marketing authorizations. Many of its intended sales are generics for drugs about to lose patent protection, but it has not decided which of those to emphasize. The firm expects big sales from antibacterial agents for contagious diseases. Ranbaxy, based in Gurgaon, India, has a presence in 49 markets, Daiichi 20. (Click here for more - a subscription may be required

You may also be interested in...

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

International Harmonization: Not Just For Audits Anymore

The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.

Reddy’s Settles On $7bn Revlimid But Natco Maintains The Lead

Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts